BPG is committed to discovery and dissemination of knowledge
Editorial Board

Yu Liang is the Director of Clinical Biomarkers at Calithera Biosciences and has over 16 years of technical expertise and strategic leadership from both academic and industry in application of genomic and genetic profiling for biomarker discovery, development of real-time PCR assays for research and companion diagnosticsand implementation of biomarker programs to support all phases of drug development pipelines. Dr. Liang is focusing on treatment of various types of solid tumors by targeting arginase and glutaminase as well as in combination with immune checkpoint inhibitors. Dr. Liang previously managed biomarker portfolios of Ibrutinib in both hematological and solid tumors at Pharmacyclics.